Coming off some recent setbacks, Immatics is rolling out its latest update on a new approach to solid tumors that’s bolstered hopes and inspired a spike in the share price of the German/US biotech as it rolls toward pivotal work next year.
At first cut, the objective response rate was 80%, which slid to 64% (7) for the 11 patients at week six in this second take of the data for IMA203 TCR-T monotherapy. Six of nine patients (67%) with multiple pre-treated tumor types hit a confirmed ORR at month three. That’s still well in the range that the company had hoped to hold the line, with evidence of durability that will be critical to prove conclusively in the trial work ahead for the biotech.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 167,200+ biopharma pros reading Endpoints daily — and it’s free.